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Abstract 
Between 70 to 80% of HIV infected patients develop anaemia which is a major complication in advanced HIV 
infection. The multifactorial etiology of the HIV-associated anaemia requires extensive studies on its unique 
pathophysiology as a step towards improving therapeutic options and disease management.The objective of this 
study is to monitor changes in serum levels of erythropoietin (Epo), Tumor necrosis factor-alpha (TNF-α), 
Interleukin-6 (IL-6), C-Reactive Protein (CRP) and anaemia in HIV infected patients over six months’ period. 
This study is Longitudinal descriptive study and it was conducted at Kenyatta National Hospital, Kenyatta 
National Hospital can be considered as Comprehensive Care Centre. 
------------------------------------------------------------------------ 
* Corresponding author.  
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2017) Volume 36, No  8, pp 90-107 
91 
 
The study used one hundred and eighty-four (184) seropositive adults aged 18 to 60 years.The results shows that 
Blood cells exhibited pathologies ranging from: Rouleaux formation, round macrocytes, microcytic 
hypochromic cells and target cells in frequencies that decreased with increase in CD4+ cells. Normochromic, 
macrocytic normochromic and dimorphic anaemias were observed. Bicytopenia (erythrocytopenia and 
leucopenia), reactive thrombocytosis with giant platelets, neutrophil and eosinophil hypersegmentations were 
also observed. Persistent increase in Epo and CRP levels were demonstrated among subjects throughout the 
study period. Increases in TNF-α levels without corresponding increase in IL-6 levels were observed. 
Persistence anaemia in presence of high Epo levels is suggestive of hyposensitivity to Epo by erythroid 
precursors. Asynchronized increases in TNF-α and IL- 6 levels may have deprived the duo the synergy required 
to effectively inhibit Epo production further facilitating the escalating levels of Epo observed. High levels of 
CRP observed indicate enhanced inflammation processes associated with HIV infection. Iron studies to rule out 
the role of iron-restricted erythropoiesis in the development microcytic, dimorphic anaemias and the 
granulocytic hypersegmentations noted are recommended. Studies on the possibility of Epo hyposensitivity 
derailing the effectiveness of recombinant human Epo in the management of HIV – associated anaemia are 
recommended.         
 Key words: Proinflamatory cytokines; erythropoietin; anaemia; Human immunodeficiency Virus. 
1.  Introduction 
Among the haematological abnormalities in HIV-infected patients, anaemia is the most common and has been 
associated with disease prognosis and poor clinical outcomes. According to World Health Organization (WHO), 
anaemia is said to occur when haemoglobin (Hb) levels fall below 12 g/dl and 13 g/dl in females and males, 
respectively. The development of HIV-associated anaemia has numerous contributors including: 
myelosuppressive drugs especially zidovudine (AZT), the virus itself, haemopoiesis – inhibiting soluble serum 
factors, antibodies against red blood cells (RBCs), infection-related gastrointestinal bleeding and hypogonadism 
in men [1,2,3,4,5]. This multifactorial origin of HIV- associated anaemia complicates not only the definition of 
its etiology but also its diagnosis and choice of therapeutic measures. With HIV- associated anaemia posing 
serious complications including poor quality of life, association with disease progression and poor clinical 
outcomes the recognition of studies of the unique pathophysiology of this anaemia as an important step towards 
improving therapeutic options and disease management cannot be underscored [6]. Erythropoietin (Epo), a 
glycoprotein hormone with a molecular weight of, 39 KDa and produced mainly in cells of kidney in adults has 
serum levels that are directly associated with those of Hb [7,8]. Human TNF-α is a glycosylated protein of 17 
KDa and a length of 157 amino acids. Interleukin 6 (IL-6) is a pleiotropic, α-helical, 22-28 KDa phosphorylated 
and variably glycosylated cytokine and plays important roles in the acute phase reaction, inflammation, 
haematopoiesis, bone metabolism, and cancer progression. C-reactive protein is synthesized in the liver and is a 
marker of inflammation. During active inflammation its blood levels rise and this rise is always accompanied by 
decrease in CD4+ cell counts in HIV infected patients, [9]. High levels of TNF-α correlate with increased risk of 
mortality and interacts with IL-6 to inhibit Epo production [10,11]. It has been observed that levels of serum 
immunoreactive erythropoietin in HIV-infected patients in various stages of illness fail to rise commensurately 
with increasing anaemia, suggesting that insufficient amounts of erythropoietin may be one cause of anaemia in 
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this setting [12]. Changes in the levels of Epo, TNF-α, IL-6 and CRP in active HIV/AIDS have been 
demonstrated in populations from industrialized countries. With Africa being home for approximately 70% of 
the global AIDS victims and Kenya in particular harboring about 1.5 million HIV infected adults studies on the 
changes in serum levels of these proteins associated with anaemia is paramount. In this study changes in serum 
levels of Epo TNF-α, IL-6, CRP and Hb among HIV infected adults in CD4+ clusters of < 200, 200-499 and ≥ 
500 cells/mm3 were monitored at intervals of three months for six months. 
2. Materials and Methods 
The study protocol was approved by Kenyatta National Hospital/University of Nairobi (KNH/UoN) ethics and 
review committee. A total of 184 HIV seropositive adults aged between 18 and 60 years were recruited 
consecutively as they consented. Both ARV- treated and ARV-naïve patients were recruited. Also similarly 
recruited were 101 HIV - seronegative blood donors as referents. Clinical and social demographic characteristics 
of the study participants were recorded. The study subjects were grouped into CD4+ < 200 (n = 22), 200-499 (n 
= 86) – and ≥ 500 cells/mm3 group based on the CD4 counts in the blood sample at recruitment. The CD4+ 
groups were further grouped into males and females: CD4+ < 200 (13 males & 9 females), 200-499 (43 males & 
43 females) - and ≥ 500 (9 males & 67 females) cells/mm3 groups. A total of 5 mls blood samples were obtained 
from each study subject at recruitment (F0), after 3 months (F1) and after 6 months (F2) during the study; while 
blood sample were obtained from the referent group at the recruitment stage only. The blood samples were then 
dispensed into EDTA vacutainers and plain tube in appropriate portions.  
The EDTA samples were used for CD4+ cell counts and haemogram determinations; while sera from blood 
samples in plain vacutainers were used for:  Epo, TNF-α, IL-6 and CRP, assays. Haemogram was done on a Cell 
TAC F Model 822® analyzer with tri level (normal, low and high) commercial controls were used for quality 
control; while peripheral blood films were stained with Leishman’s stain. The CD4+ counts were done on a 
FACS CALIBUR®   machine that used commercial controls set at zero, low, medium and high concentrations 
for quality control. CRP assays were carried out in a fully automated instrument, Humastar 600® that was 
calibrated with normal and pathological controls and with 2 levels of “Turbidos” control. Erythropoietin, TNF-
α, IL-6 assays were done using Thermo Scientific® quantitative sandwich enzyme immunoassay technique on 
HumaReader HS® Elisa reader. The concentrations of the tests were read off curves constructed using serially 
diluted commercial standards. Parameters that demonstrated significant differences between male and female 
means among the referents were analyzed under the separate genders in HIV positive respondents; where no 
such differences were demonstrated the parameters were analyzed without regard to gender.  
 The raw data obtained was recorded into laboratory note book, entered into excel computer data base then after 
cleaning and verification transported into statistical package for the social sciences (SPSS) version 21 and 
analysis done there-in. Means, medians, standard error of the mean, minimum and maximum ranges were 
determined. Comparison of the means between males and females; between HIV negative and HIV positive 
respondents was done using student - t test. HIV negative respondents’ 95% confidence interval (CI) was used 
as reference ranges to determine frequencies of increased or decreased parameters of HIV positive respondents. 
Peripheral blood films were microspically examined for pathologies and their frequencies determined and 
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tabulated. 
3. Results 
Demographic characteristics of the respondents is presented in Table 1. For the HIV negative control group, the 
mean age was 30.2 years, 74.3 % were male, 63.4% had tertiary education, 45.5% were students, 95 % were 
non-smokers and 75.2% did not consume alcohol. For the HIV positive group, the mean age was 39.7, 64.7% 
were females, 43.5% had secondary education, 51.1% were employed, 98.9 % were non-smokers and 88% were 
teetotaler.  
Table 1: Demographic characteristics of the respondents. 
 
 
The CD4+ levels for all the respondents was determined at the commencement of the study and also on the third 
and sixth months, for the HIV infected individuals. Baseline data indicated that the CD4+ counts for the HIV 
negative control group averaged 780.9 ±31.2 cells /mm3 while that of the HIV positive individuals was 333.0 ± 
19.7 cells / mm3. Follow up data on the HIV positive respondents indicated that the CD4+ levels at three and six 
months were elevated to 501.6±25.4 and 497 ± 19.7 cells / mm3, respectively.  
When the HIV respondents were categorized into three groups, according to WHO guidelines, it was found that 
in the group with less than 200 cells/mm3 it averaged 119 ± 15.1 cells/mm3; for CD4+ 200 – 499 cells/mm3 
group it was 376.5 ±19.9 cells/mm3; while in CD4+ >500 cells/mm3 the group average was 723.8 ± 32.2 
cells/mm3.  Of the respondents 152 (82.6%) were ARV-treated and 32 (17.4 %) were ARV- naïve with their 
CD4+ cell counts of 502.7 ± 23.5 and 562.7± 68.6 cells/mm3, respectively (Table 2). 
Mean± Min- 95% CI Mean± Min- F(%) 95% CI
Variable SEM  Max SEM Max N = 101
Age (yr) 39.7±0.63 19-59 26.1-53.3 30.2±0.96 18-56 28.3-32.1
None 12.3-22.9 1 (1%) 0.2-5.3
Primary 17.8-29.8 10 (9.9%) 3.4-17.1
36-50 26 (25.7%) 18.9-35.8
Tertiary 27-40.3 64 (63.4%) 54.7-72.9
None 0.1-2.0 1 (1%) 1.2-5.3
2.9-9.5 0 (0%) 0.2-5.3
Business 37-51 24 (23.8%) 15.2-32.3
42.7-56.8 30 (29.7%) 22.1-39.1
Student 1.1- 6 46 (45.5%) 35.4-54.3
Smoking
Yes 0.5- 4.6 5 (5%) 2.7-12.1
No 95.4-99.5 96  (95%) 87.9-97.3
Alcohol
Yes 8.5-17.6 25 (24.8%) 17.9-34.4
No 82.4-91.8 76 (75.2%) 65.6-82.1
Secondary
Occupation
House wife
Employed
HIV - positive HIV- negative
Education
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Table 2: Baseline levels of CD4 counts among the HIV positive respondents. 
 
4. Blood cell pathologies 
The referents displayed normal red blood cells with diameters almost the same size as that of the nucleus of a 
small mature lymphocyte. While the tests groups showed pathology that ranged from microcytic hypochromic, 
round macrocytes, rouleaux formation to target cells. The frequencies of these pathology is presented in Table 3. 
In the group with CD4+ levels less than 200 cells/mm3 the baseline distribution of the pathology was as follows:  
rouleaux formation (27.3%), macrocytosis (22.7%), hypochromasia (13.6 %) and targeting (9.1%), all of which 
exhibited a decline in frequency six months later (Table 3).  In the CD4 200–499 cells/mm3 group the 
macrocytosis frequency was 10.4% at the screening stage and this continuously dropped to 2.3 % and 1.1% after 
the third and sixth month, respectively. While the rouleaux frequency of 2.3% that was observed at the 
screening stage was found to stabilize at 1.1% in the follow up samples. For hypochromasia the frequency of 
2.3% that was recorded during screening was found to disappear after three months but it re-immerged after six 
months at a higher frequency of 4.7%. In the CD4, 200–499 cells/mm3 group, the target cells (2.3%) were only 
observed in the sixth month of the study. For the CD4+ ≥ 500 cells/mm3 group the macrocytosis of 10.5 % 
observed during screening was found to stabilize at 5.3 % in follow up samples; for rouleaux formation it was 
stable at 3.9% in the first three months before it declined to 2.3% at the end of the study. However, for target 
cells there was mixed results (Table 3).  
In the referent group and those that were HIV positive with CD4+ levels of < 200cells/mm3 no white cell 
pathology was reported in the six months of study. However, HIV positive respondents in CD4+ levels of 200 – 
499 and ≥ 500 cells/mm3 groups demonstrated the hypersegmentation of neutrophil and eosinophils. For the 
group with CD4+ levels at 200 – 499 the neutrophil hypersegmentation dropped from 11.6% to 0 % after three 
months, then rose to 2.3% after the six month; while that of eosinophil dropped from11.6% to 0% after three 
months. In CD4+ ≥ 500 cells/mm3 group neutrophil and eosinophil hypersegmentation frequency decreased 
from 2.6% to 1.3 % in the six months of the study. There was no pathology observed in the HIV negative 
control. However, HIV – infected respondents showed giant thrombocytes.  In the group with CD4+ 200 – 499 
the platelet giant cells were only observed in the baseline sample (1.2%) while in the group that had CD4+ 
levels ≥ 500 cells/mm3 the pathology was observed at inception and in the first three months (1.3%) (Table 3).  
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Table 3: Frequency (%) of observed blood cell changes in the respondents. 
 
                                    F0 = baseline stage; F1 = Follow up at 3 months; F2 = Follow up at 6 months 
4.1. Differences in haematological parameters in HIV negative respondents 
Significant differences between male and female HIV negative respondents (referents) were observed in: red blood 
cells (4.9±0.08 x 10 12/l versus 4.5±0.12 x10 12/l, p = 0.008), haemoglobin (13.9±0.22 g/dl versus 12.2±0.31 g/dl, p < 
0.001), mean cell volume (86.8± 0.64 fl versus 82.4±1.69 fl, p = 0.019), white blood cells (5.2±0.14x109 /l versus 
6.5±0.25x109/l, p < 0.001), neutrophils (2.3±0.9x109/l versus 3.2±0.22x109 /l, p < 0.001), lymphocytes 
(2.1±0.08x109 /l versus 2.5±0.12x109 /l, p = 0.007), CD4+ (703.1±32.2 cells/mm3 versus 542±59.4 cells /mm3, p < 
0.001) and platelets (248.4±9.6 x109 /l versus 302.9 ±17.61 x 109/l , p = 0.009) as shown in table 4. 
Table 4: Differences in haematological parameters in HIV negative respondents 
 
WBC (white blood cells), N (neutrophil), L (lymphocyte), E (eosinophil), RBC (red blood cell), MCV (mean cell 
N = 22 N = 86 N = 76
F0 F1 F2 F0 F1 F2 F0 F1 F2
6 (27.3%) 3 (13.6%) 1 (4.5%) 2 (2.3%) 1 (1.1%) 1 (1.1%) 3 (3.9%) 3(3.9%) 2 (2.3%)
2 (9.1%) 1 (4.5%) 0 (%) 0 (0%) 0 (0%) 2 (2.3%) 0 (0%) 2 (2.3%) 1 (1.3%)
3 (13.6%) 4 (18.2%) 1 (4.5%) 2 (2.3%) 0 (0%) 4 (4.7%) 0 (0%) 6 (7.9%) 3 (3.9%)
5 (22.7%) 1 (4.5%) 1 (4.5%) 9 (10.4%) 2 (2.3%) 1 (1.1%)8 (10.5%)4 (5.3%) 4 (5.3%)
 0 (0%) 0 (0%) 0 (0%) 10 (11.6% 0 (0%) 2 (2.3%) 2 (2.6%) 2 (2.3%) 1 (1.3%)
0 (0%) 0 (0%) 0 (0%) 10 (11.6%) 0(0%) 0 (0%) 2 (2.6%) 1 (1.3%) 1 (1.3%)
0 (0%) 0 (0%) 0 (0%) 1 (1.2%) 0 (0%) 0 (0%) 1 (1.3%) 1 (1.3%) 0 (0%)
Microcytic hypochromic cells
Round macrocytes
Neutrophil hypersegmentation
Eosinophil hypersegmentation
Giant platelets
Morphological Change CD4 + < 200 cells/mm3 CD4+ 200 - 499cells/mm3 CD4+ ≥ 500 cells/mm3
Rouleaux formation
Target cells
Males(n=75)                                 
95% CI
RBC x 1012/l 4.8 (0.06) 4.6- 4.9 4.9 (0.08) 4.7- 5.0 4.5 (0.12) 0.008**
Hb g/dl 13.5 (0.21) 13.1-13.9 13.9 (0.22) 13.5-14.4 12.2 (0.31) < 0.001**
MCV Fl 85.7 (1.12) 84.4- 87 86.8 (0.64) 85.6-88.1 82.4(1.69) 0.019*
MCH g/l 28.5 (0.46) 27.9-29 28.8 (0.29) 28.2-29.3 27.6 (0.67) 0.111
MCHC g/l 33.2(0.16) 32.9-33.5 33.1 (0.20) 32.7-33.5 33.4 (0.25) 0.334
WBC x 109/l 5.5 (0.14) 5.2- 5.8 5.2 (0.14) 4.9- 5.4 6.5 (0.25) < 0.001**
Nx109/l 2.5 (0.01) 2.3- 2.7 2.3 (0.09) 2.1-2.5 3.2 (0.22) < 0.001*
Lx109/l    2.2 (0.07) 2.0-2.3 2.1 (0.08) 1.9-2.2 2.5 (0.12) 0.007**
Mx109/l 0.4 (0.04) 0.4-0.5 0.4 (0.02) 0.3-0.5 0.5 (0.04) 0.05
Ex109/l 0.2 (0.02) 0.2-0.3 0.2 (0.02) 0.2-0.3 0.2 (0.02) 0.19
CD4+ /mm3 780.9 (31.22) 718.9-842.8 703.1(32.22) 683.8-767.5 542 (59.44) < 0.001**
Px109/l 262.4 (8.71) 245.1-279.7 248.4 (9.56) 229.4-267.4 302.9 (17.61) 0.009**266.6-339.2
95% CI Mean(SEM)
2.2-2.7
0.1-0.2
882.7-1127.6
6.0-7.1
2.8-3.6
2.2-2.7
78.9-85.9
26.2-28.9
32.9-33.9
95% CI P-value
4.2- 4.7
11.6-12.9
Parameter Mean (SEM) Mean (SEM)
Respondent group
HIV Negative all (N=101) Females(n = 26)                               
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volume), MCH 
(mean cell haemoglobin), MCHC (mean cell haemoglobin), P (platelet). ** Significant difference at p < 0.01 (one-
tailed), 
* Significant difference at P < 0.05 (two-tailed) using t-test. 
4.2. Frequency of haematological abnormalities among HIV positive male   respondents 
The frequency of erythrocytopenia (RBC < 4.7 x 1012/l) decreased progressively from 92.3 % to 84.6% then to 
61.5% in baseline, third and sixth months of the study respectively in the CD4+ cells < 200 cells / mm3 group. In 
CD4+ 200 – 499 cells /mm3 group however, the frequency decreased from the baseline frequency level of 61.5% to 
48.8% then increased to 51.2% in the third and sixth months respectively; while the frequency remained constant at 
22.2 % throughout the study period in CD4+ ≥ 500 cells / mm3 group. The highest frequency of anaemia (Hb < 13.5 
g/dl) was observed in CD4+ < 200 cells / mm3 group and decreased from 69.2% to 53.8% then to 38.5% in the 
baseline, third and sixth months of the study respectively. In the CD4+ 200 -499 cells/mm3 group the frequency of 
anaemia decreased from the baseline level of 30.2% to 23.3% then to 14 % in the third and sixth months of the study 
respectively. The frequency of anaemia decreased by three times in the third month (from baseline level of 33.3% to 
11. 1%) then doubled (to 22.2%) in the sixth month of study in the CD4+≥ 500 cells / mm3 group (Table 5).  
The frequency of macrocytosis (MCV > 88.1 Fl) increased from the baseline level of 69.2% and stabilized at 76.9% 
in the third and sixth months of the study in the CD4 < 200 cells/mm3 group. The level of the abnormality decreased 
from a stable frequency level of 74.4%, observed at baseline and three months’ periods to 72.1% in the sixth month 
of the study in CD4+ 200 – 499 cells / mm3 group; while it remained at 100% throughout the study period in CD4+ 
≥ 500 cells / mm3 group. Leucopenia (WBC < 4.9 x 109/l) demonstrated the highest frequency level of 76.9% in 
CD4+ < 200 cells / mm3 group throughout the study period. The abnormality decreased in frequency from baseline 
level of 51.2% to 39.5% in the third month of the study, then increased to 58.1 % during the sixth month of the study 
in the CD4+ 200 – 499 cells / mm3 group. This abnormality decreased from the baseline level of 33.3% to 22.2% in 
the third month and then decreased further to 11.1% in the sixth month of the study in the CD4+ ≥ 500 cells /mm3 
group (Table 5)  
 Neutropenia (N < 2.2 x 109/l) levels decreased from the baseline frequency level of 53.8% to 46.2% in the third 
month then increased again to 61.5% in the sixth month of the study in CD4+ < 200 cells/mm3 group. The 
abnormality however, demonstrated a steady increase from the baseline frequency level of 41.9% to 51.2 % then to 
62.8% during the third and sixth months respectively in the CD4+ 200 - 499 cells/mm3 group. In the CD4+ ≥ 500 
cells /mm3 group, neutropenia frequency levels decreased from the baseline level of 33.3% to 22.2 % then to 11.1% 
in the third and sixth months respectively during the study. Lymphocytopenia (L < 1.9 x 109/l) decreased from the 
baseline level of 84.6% and stabilized at 53.8% in the third and sixth months of the study in the CD4+ < 200 cells / 
mm3 group. The abnormality decreased from the baseline frequency level of 67.4% to 41.9% then to 2.3% in the 
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third and sixth months of the study respectively in CD4+ 200 – 499 cells / mm3 group. This abnormality increased 
from the baseline frequency level of 22.2% to 33.3% in the third month of the study and then completely resolved to 
0 % by the sixth month of the study in the CD4+ ≥ 500 cells /mm3 group. During the study, the highest frequency 
level of thrombocytosis of 61.5% was observed at baseline and in the third month which then decreased to 46.2% in 
the sixth month in CD4+ < 200 cells / mm3 group.  The frequency of this abnormality increased from the baseline 
level of 46.5% to 48.8% in the third month, then decreased to 39.5% in the sixth month of the study in the CD4+ 
200 – 499 cells / mm3 group; while it remained at the baseline frequency level of 55.6% during the first three 
months of the study and then decreased to 33.3% in the sixth month (Table 5).  
Table 5: Frequency of haematological abnormalities among HIV positive male respondents 
 
                            F0 = baseline stage; F1 = Follow up at 3 months; F2 = Follow up at 6 months 
4.3. Frequency of haematological abnormalities among HIV positive female respondents  
The frequency levels of erythrocytopenia (RBC < 4.2x 10 12 /l) increased from the baseline level of 44.4 % to a 
stable level of 77.8% up to the end of the study period in CD4+ < 200 cells / mm3 group. The abnormality decreased 
from the baseline level of 51.2 % to 46.1% in the third month and then increased to 48.8% in the sixth month in the 
CD4+ 200-499 cells /mm3 group. In CD4+ ≥ 500 cells/mm3 group, erythrocytopenia levels decreased from the 
baseline frequency level of 52.2% to 47.8% in the third month and then increased to 53.7% in the sixth month. The 
Parameter F0                              F1 F2 F0 F1 F2 F0 F1 F2
RBC x 10 12/4.7 - 5.0
12 (92.3)     11 (84.6) 8 (61.5) 21 (48.8) 22 (51.2) 19 (44.2) 2 (22.2) 2 (22.2) 2 (22.2)
Hg g/dl 13.5 - 14.4
anaemia
9 (69.2)       7 (53.8) 5 (38.5) 13 (30.2) 10 (23.3) 6 (14) 3 (33.3) 1 (11.1) 2 (22.2)
MCV Fl 85.6 - 88.1
9 (69.2)      10 (76.9) 10 (76.9) 32 (74.4) 32 (74.4) 31 (72.1) 9 (100) 9 (100) 9 (100)
WBC x 109/l 4.9 - 5.4
10 (76.9)     10 (76.9) 10 (76.9) 22 (51.2) 17 (39.5) 25 (58.1) 3 (33.3) 2 (22.2) 1 (11.1)
Nx109/l 2.1- 2.5
7 (53.8)         6 (46.2) 8 (61.5) 18 (41.9) 22 (51.2) 27 (62.8) 3 (33.3) 2 (22.2) 1 (11.1)
L x 109/l 1.9 - 2.2
11 (84.6)       7 (53.8) 7 (53.8) 29 (67.4) 18 (41.9) 21 (2.3) 2 (22.2) 3 (33.3) 0 (0)
P x 109/l 229.4 - 276.4
8 (61.5)         8 (61.5) 6 (46.2) 20 (46.5) 21 (48.8) 17 (39.5) 5 (55.6) 5 (55.6) 3 (33.3)
Frequency (%) of 
Lymphocytopenia
(L < 1.9 x 109/l)
Frequency (%) of 
Thrombocytosis
(P > 276.4 x 109/l)
Frequency (%) of 
Leucopenia
(WBC< 4.4 x 109/l)
Frequency (%) of 
Neutropenia
(N< 2.1x x109/l)
RBC < 4.7 x 1012/l)
Frequency (%) of 
 (Hb < 13.5g/dl)
Frequency (%) of 
Macrocytosis
(MCV > 88.1 fl)
CD4+ < 200 cells / mm3 (   CD4+ 200 – 499 cells /mm3 (n=43) CD4+ ≥ 500 cells /mm3 ((n= 9)
Frequency (%) of 
Erythrocytopenia
Respondent group
HIV positive
Males (n=75)
95% C.I 
HIV positive males (n = 65)
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level of anaemia (Hb < 11.6 g/dl) increased from the baseline frequency level of 66.7% to 88.9% in the third month 
then decreased to 66,7% in the sixth month in the CD4+ < 200 cells/mm3 group. The abnormality increased from the 
baseline frequency level of 25.6 % to 27.9% in the third month then increased further to 37.2% in the sixth month in 
CD4+ 200 – 499 cells/mm3 group. In CD4+ ≥ 500 cells/mm3 group, the level of anaemia increased from the baseline 
frequency level of 35.8% to 40.3% in the third month, then decreased to 35.8% in the sixth month. The frequency 
level of macrocytosis (MCV >85.9 fl) remained at 55.6% during the entire study period in CD4+ < 200 cells / mm3; 
while in CD4+ 200 – 499 cells /mm3 group the frequency levels increased from the baseline level of 62.8% to 65.1% 
in the third month then increased further to 67.4% in the sixth month during the study. 
 The baseline macrocytosis frequency level of 73.1% decreased to 68.7% in the third month and increased to 71.6% 
during the sixth month of the study in CD4+ ≥ 500 cells / mm3 group (Table3c).  In the CD4+ < 200 cells / mm3 
group’s baseline leucopenia (WBC < 6.0 x 109/) frequency level of 88.9% decreased after three months and 
stabilized at 77.8% for rest of the study period. Leucopenia increased from the baseline frequency level of 69.8% to 
74.4% and then to 79.1% in the third and sixth months of the study in CD4+ 200 – 499 cells / mm3 group. In CD4+≥ 
500 cells / mm3 group the baseline leucopenia frequency level of 59.7% decreased to 50.7% in the third month and 
then increased marginally to 53.7% in the sixth month of the study. Baseline neutropenia (N < 2.8 x 10 9 /l) 
frequency level of 66.7% decreased to 55.6% in the third month then increased to 77 8% in the sixth month in CD4+ 
< 200 cells / mm3 group during the study. In CD4+ cells 200 – 499 cells / mm3 the baseline neutropenia frequency 
level of 51.2 % increased to 58.1 % in three months and then increased further to 69.8% in the sixth month of the 
study. The baseline neutropenia frequency level of 61.2 % decreased markedly to 11.9%, then increased markedly to 
62.7% in the third and sixth months respectively.in CD4+≥ 500 cells /mm3 group (Table 6). 
The baseline lymphocytopenia (L < 2.2 x 109/l) frequency level of 100% observed in CD4+ < 200 cells /mm3 group 
decreased drastically to 11.1 % and then increased markedly to 66.7% in the third and sixth months respectively 
during the study. The frequency level of the abnormality in CD4+ 200 – 499 cells /mm3 group decreased from the 
baseline level of 72.1% to 62.8% then increased to 67.4% in the third and sixth months respectively during the 
study.  In the CD4+ ≥ 500 cells /mm3 group, lymphocytopenia baseline frequency level of 44.8% decreased to 
28.4% in the third month then increased to 41.8% in the sixth month. Finally, the frequency levels of thrombocytosis 
(P >339.3 x 10 9 /l.) observed in the CD4+ < 200 cells / mm3 increased   from the baseline level of 22.2% to 44.4% 
then decreased again to 22.2% in the third and sixth months of the study respectively.  
In CD4+ 200 – 499 cells /mm3 group the frequency level of thrombocytosis at baseline was 41.9% and remained 
unchanged in the next three months but decreased to 6.5% in the sixth month of the study. The frequency level of 
thrombocytosis demonstrated marginal changes in the CD4+ ≥ 500 cells /mm3 group with a decrease from the 
baseline level of 37.3% to 28.4% in three months followed by marginal increase to 29.9% in the sixth month of the 
study (Table 6).  
 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2017) Volume 36, No  8, pp 90-107 
99 
 
Table 6: Frequency of haematological abnormalities among HIV positive female respondents 
 
F0 = baseline stage; F1 = Follow up at 3 months; F2 = Follow up at 6 months 
4.4. Frequency of abnormalities of Epo, TNF- α, IL-6 and CRP parameters among the HIV 
 positive respondents 
The frequency of increased serum Epo levels (Epo >368.9 pg./ml) decreased from the baseline level of 90.9% to 
stable level of 77.3% at the third month to the end of the study period in CD4+ < 200 cells /mm3 group. In CD4+ 
200 – 499 cells / mm3 group the Frequency levels of increased serum Epo decreased from the baseline level of 
41.9% to 15.1 then increased to 37.2 in the third and sixth months respectively; while in the CD4+ ≥ 500 cells / mm3 
group the baseline frequency level of 76.3% decreased to 73.7% and then increased to75% in the third and sixth 
months respectively during the study. The frequency of increased serum levels of tumor necrosis factor – alpha 
(TNF-α >7.0 pg./ml) decreased from the baseline level of 72.7% to 31.8 % in the third month then increased two-
fold to 63.6% in the sixth month in CD4+ < 200 cells / mm3 group during the study. In CD4+ 200 – 499 cells /mm3 
group, the baseline frequency of increased TNF-α serum level of 41.9% decreased to 15.1% in the third month and 
then increased to 37.2 % by the sixth month of the study; while in CD4+≥ 500 cells / mm3 group the baseline 
frequency level 28.9% decreased to 11.8 % by the third month then increased to 25% in the sixth month of the study 
(Table 7). 
Respondent group
HIV negative
Females
Parameter 95% CI Abnormality F0 F1 F2 F0 F1 F2 F0 F1 F2
RBC x 10 12/l 4.2 - 4.7 Frequency (%) of 
Erythrocytopenia
RBC < 4.2x1012/l 4 (44.4) 7 (77.8) 7 (77.8) 22 (51.2) 20 (46.1) 21 (48.8) 35 (52.2) 32 (47.8) 36 (53.7)
Hb g/dl 11.6-12.9 Frequency (%) of 
Anaemia 
(Hb < 11.6g/dl) 6 (66.7) 8 (88.9) 6 (66.7) 11 (25.6) 12 (27.9) 16 (37.2) 24 (35.8) 27 (40.3) 24 (35.8)
MCV fl 78.9-85.9 Frequency (%) of 
macrocytosis
MCV > 85.9 Fl 5 (55.6) 5 (55.6) 5 (55.6) 27 (62.8) 28 (65.1) 29 (67.4) 49 (73.1) 46 (68.7) 48 (71.6)
WBCx109/l 6.0 - 7.1 Frequency (%) of 
Leucopenia
(WBC<6 x 109/l) 8 (88.9) 7 (77.8) 7 (77.8) 30 (69.8) 32 (74.4) 34 (79.1) 40 (59.7) 34 (50.7) 36 (53.7)
Nx109/l 2.8-3.6 Frequency (%) of 
Neutropenia
(N < 2.8x109/l) 6 (66.7) 5 (55.6) 7 (77.8) 22 (51.2) 25 (58.1) 30 (69.8) 41 (61.2) 8 (11.9) 42 (62.7)
Lx10 9 /l 2.2 - 2.7 Frequency (%) of 
Lymphopenia
(L < 2.2 x109/l) 9 (100) 1 (11.1) 6 (66.7) 31 (72.1) 27 (62.8) 29 (67.4) 30 (44.8) 19 (28.4) 28 (41.8)
P x10 9/ l 266.6-339.2 Frequency (%) of 
Thrombocytosis
(P >339.2 x 109/l) 2 (22.2) 4 (44.4) 2 (22.2) 18 (41.9) 18 (41.9) 20 (53.5) 25 (37.3) 19 (28.4) 20 (29.9)
CD4+ < 200 cells/mm3
HIV positive females (N = 119)
CD4+ ≥ 500 cells/mm3CD4+ 200 - 499 cells/mm3
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The frequency levels of increased serum interleukin – 6 levels (IL-6 >2.6 pg. /ml) was 9.1% in CD4+ < 200 cells / 
mm3 group and 9.3% in CD4+ 200 – 499 cells / mm3 group throughout the study period. In CD4+ ≥ 500 cells / mm3 
group however, the baseline frequency levels of 7.9% increased to 17.1% in the third month and then decreased to 
9.2 % in the sixth month of the study. The frequency of increased C- Reactive Protein serum levels (CRP > 4.0 mg 
/ml) increased from the baseline level of 77.3% to 81.6 % in the third month and then decreased to 63.6% by the 
sixth month in CD4+ < 200 cells / mm3 group during the study. In CD4+ 200 – 499 group the abnormality 
demonstrated an increase from the baseline frequency level of 54.7% to 62.8% by the third month a further increase 
to 70.8% by the sixth month of the study period. Baseline frequency levels of 55.3% increased to 67.1 % in the third 
month and then decreased to 56.6% by the sixth month in CD4+≥ 500 cells / mm3 group during the study period 
(Table 7). 
Table 7: Frequency of abnormalities of Epo, TNF- α, IL-6 and CRP parameters among the HIV positive 
respondents 
 
F0 = baseline stage; F1 = Follow up at 3 months; F2 = Follow up at 6 months 
5.  Discussions 
Anaemia occurs in both ARV-treated and ARV-naïve HIV patients with multifactorial etiology. The complications 
associated with anaemia in advanced stages of HIV/AIDS requires concerted research studies to understand the 
unique pathophysiology of HIV- associated anaemia. This study was designed to prospectively monitor changes in: 
blood cell morphologies, proteins and cytokines that influence blood cell development in order to morphologically 
classify the observed anaemia as well as determine the accompanying changes in serum levels of Epo, TNF- α, IL-6 
and CRP.                                    
HIV negative
All (n = 101)
Parameter 95%CI Abnormality F0 F1 F2 F0 F1 F2 F0 F1 F2
EPO pg/ml 294.3 -368.9 Frequency (%)
 of increased levels
(EPO > 368.9 pg/ml) 20(90.9) 17(77.3) 17(77.3) 74(86) 62(72.1) 63(73.3) 58(76.3) 56(73.7) 57(75)
TNF-α pg/ml 5.-7.0 Frequency (%) of
increased levels
(TNF-α > 7.0 pg/ml) 16(72.7) 7(31.8) 14(63.6) 36(41.9) 13(15.1) 32(37.2) 22(28.9) 9(11.8) 19(25)
IL-6 pg/ml 1.6 - 2.6 Frequency (%) of 
increased levels
(IL-6 > 2.6 pg/ml) 2(9.1) 2(9.1) 2(9.1) 8(9.3) 8(9.3) 8(9.3) 6(7.9) 13(17.1) 7(9.2)
CRP mg/ml 2.7 - 4.0 Frequency (%)
of increased levels
(CRP > 4.0 mg/ml) 17(77.3) 18(81.8) 14(63.6) 47(54.7) 54(62.8) 61(70.9) 42(55.3) 51(67.1) 43(56.6)
CD4+< 200 cells/mm3 (n=22) CD4+ 200 - 499 cells/mm3 (n= 86) CD4+ ≥ 500 cells/mm3 (n= 76)
HIV positive all (n = 184)
Respondent group
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The significantly higher WBC mean values in females than in males has not been previously documented. The 
various erythrocyte pathologies that included: rouleaux formation, round macrocytes and microcytic hypochromic 
changes observed among the HIV positive respondents in the study have been previously reported to characterize 
HIV-associated anaemia [13]. The etiology of microcytic hypochromic features has been linked to: iron deficiency, 
chronic disease and congenital haemoglobinopathies including thalassemia; while that of macrocytic normochromic 
changes has been associated with: alcoholism, liver disease, hypothyroidism and side effects of certain medications 
such as those used to treat cancer, seizures and autoimmune disorders [14,15]. In this study there was no evidence of 
congenital haemoglobinopathies from the blood film evaluations and 88% of the respondents were teetotaler from 
the information on the questionnaire filled in by the study respondents. Moreover, 152 out of the total 184 (82.6%) 
HIV positive respondents were on antiretroviral therapy. Therefore, microcytic hypochromic features observed were 
possibly due to chronic illness and /or iron deficiency; while round macrocytes were associated with antiretroviral 
therapy. Indeed, macrocytic anaemia has been reported to arise from reduced erythropoiesis complicated by drug 
therapy [16,17]. Rouleaux formation has been associated with anaemia, hypovolemia and acute - phase proteins, 
particularly fibrinogen and low albumin levels [18,19].  The other erythrocyte pathology observed in the study was 
presence of target cells. Target cells have been associated with haemoglobinopathies and liver diseases [20]. In this 
study however, their presence may be attributed to possible liver disorder secondary to HIV infection. The 
frequency levels of rouleaux formation, target cells and microcytic hypochromic cells were highest in CD4+ < 200 
cells / mm3 and decreased in the higher CD4+ cell count groups (CD4+ 200 - 499- and ≥ 500 cells / mm3). 
Reduction in the levels of these red cell changes with increases in CD4+ cell counts signifies decreases in the degree 
of HIV- associated pathology since changes in CD4+ cell counts have been reported as markers for HIV disease 
progress [21].                                                                                                        
Highest levels of erythrocytopenia were observed in CD4+ < 200 cells/mm3 group. This is   suggestive of 
suppressed erythropoiesis by HIV infection whose degree is dependent on the severity of the disease. Previously it 
has been reported that there is inhibition of haemopoiesis by HIV infection [22]. The level of observed anaemia 
decreased with increases in CD4+ cell counts in both males and females but generally anaemia levels were higher in 
females than in males. Higher levels of anaemia in females than in males may be explained partly by the fact that 
there is increased iron needs in women of child-bearing age [23,24,25]. The level of observed macrocytosis 
increased with increases in CD4+ cell counts; while microcytic hypochromic cells observed in microscopy spread 
across all the CD4+ groups.  Morphologically three types of anaemia were observed: normocytic normochromic, 
macrocytic and dimorphic with normocytic normochromic dominating in CD4+ < 200 cells/mm3 group, macrocytic 
dominating in both CD4+ 200 -499- and CD4+ ≥ 500 cells/mm3 groups and dimorphic anaemia spread in all the 
CD4+ cell groups. have Normocytic normochromic (40.4%), dimorphic anaemia (18.8%) and microcytic 
hypochromic anaemia (7.2%) in HIV antiretroviral (ARV) naïve patients has been reported [26]; while in HIV 
infected patients on ARV therapy they demonstrated anaemia in the following distribution: normochromic anaemia 
(63.88%), microcytic, hypochromic anemia (19.44%), macrocytic anemia (2.8%) and dimorphic anemia (13.88%) 
[26]. It has also been reported that treatment with zidovudine (AZT) inferred macrocytic anaemia of 34.62% [27]. 
These levels of red cell pathologies were not derived from respondents classified into CD4+ cell groups and so 
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could not be directly compared with those of this study. All these observations show that both HIV infection and 
ARV therapy singly or in combination can cause anaemia in HIV/AIDS.                                                                                   
Other blood cell changes observed in this study included: neutropenia, lymphocytopenia and monocytopenia. These 
observations agree with other studies that have associated pancytopenia with HIV infection arising from suppression 
of haemopoiesis by the virus itself and by haemopoiesis - inhibiting soluble serum factors [2,28,29]. High levels of 
neutropenia observed in this study compare well with that of 70% reported before [30]. Moreover, high levels of 
observed lymphocytopenia with levels that generally decreased with increases in CD4+ counts compare well with 
the levels previously reported: 84% [26], 28% [31], and 23% [32]. Lymphocytopenia in HIV infection has been 
reported to arise from lymphocyte depletion through antibody-dependent cytotoxicity mechanisms [33]. Decrease in 
the levels of lymphocytopenia with increases in CD4+ counts show that lymphocytes are markers of changes in CD4 
levels. This supports previous reports that have recommended the use of absolute lymphocyte counts in place of 
CD4+ counts in resource-limited settings [34,35].                                                                                  
Neutrophil and eosinophil hypersegmentations of slight to moderate levels were observed in this study. Previously 
these pathologies have been reported to be classically pathognomonic of the megaloblastic anaemias, often caused 
by vitamin B12 or folate deficiencies, or DNA-replication poisons and manifesting with presence of oval macrocytes 
in peripheral blood film [15]. Recent reports however, have strongly associated neutrophil hypersegmentations with 
iron deficiency anaemia [35,36,37,38,39]. Peripheral blood film examination is an indispensable tool to the 
haematology practice and is interpreted together with results of automated blood cell counts [40]. Blood film 
evaluations in this did not show any oval macrocytes to support the association of vitamin B12 or folate deficiencies, 
or DNA-replication poisons with the macrocytic changes observed. This observation therefore supports the reports 
that associate the granulocytic hypersegmentation with iron deficiency.  
Slight thrombocytosis observed in this study was accompanied by giant platelets. Other reports have however, 
observed thrombocytopenia in HIV infection [26,36], possibly as a component of pancytopenia that is said to 
characterize the disease [28,29]. Conditions that give rise to reactive or secondary thrombocytosis include: 
haemorrhage, acute infections, iron deficiency, cancer and splenectomy or hyposplenism [41,42]. In HIV infection 
thrombocytosis is reported to arise from compensatory thrombopoietin production [43]. The actual cause of the 
observed thrombocytosis in this study could not be fully explained but thrombopoietin assay could possibly give 
clear inferences.  
In this study there was no gender-based significant differences observed in mean values of erythropoietin (Epo), 
tumor necrosis factor-alpha (TNF- α), interleukin-6 and C - Reactive Protein (CRP) in HIV negative respondents, 
although gender-based reference ranges for the parameters have been reported elsewhere among the Caucasians 
[44]. Nevertheless, this is in keeping with the reports that there are differences in reference values between people of 
African descent and Caucasians [45,46].    
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Among the HIV positive respondents there were markedly increased levels of erythropoietin in all the CD4+ cell 
groups. Increases in Epo levels in HIV infection have been previously reported [7,8]. However, some reports have 
attributed HIV-associated anaemia to inadequate levels of Epo arising from circulating auto-antibodies against 
endogenous Epo [12,47]. These antibodies have been reported to arise from molecular mimicry between Epo and the 
HIV-1 p17 protein [47]. This study’s findings however, disagree with the reports that associate anaemia in HIV with 
Epo deficiency and instead propose hyposensitivity to Epo or Epo resistance as the cause of HIV-associated 
anaemia. This is in line with the in vitro studies that have shown that progenitor cells from HIV infected patients 
were intrinsically refractory to the growth effects of Epo, resulting in accumulation of colonies at a relatively 
undifferentiated stage of erythroid development [6]. There was slight to marked increases in TNF- α distributed in 
all the CD4+ cell groups. Increases in TNF- α in HIV infection has been reported previously [49,50]. In addition, 
there were slight increases in interleukin - 6 levels distributed in all the CD4+ cell groups. Previous studies have 
reported that increases in TNF- α and IL-6 in HIV synergistically inhibit Epo synthesis [51]. The frequency levels of 
increases in TNF- α observed in this study were much higher than those of IL-6 increases and possibly because of 
this imbalance, the two cytokines could not inhibit Epo synthesis resulting in the observed Epo increases. There 
were moderate to marked increases in CRP levels which decreased with increases in CD4+ cells. Increases in CRP 
as a proinflammatory protein in HIV has already been reported [52,53]. 
6.  Conclusion 
 Among HIV negative respondents significantly higher WBC mean values in females than in males were 
established. HIV positive respondents demonstrated anaemia levels that reduced with increases in CD4+ cells; the 
anaemia was classified morphologically into normocytic normochromic, macrocytic normochromic and dimorphic. 
Also demonstrated was bicytopenia (erythrocytopenia and leucopenia) which was thought to be due to the 
suppression of haemopoiesis by the virus itself and / or by haemopoiesis- inhibiting soluble serum factors. The 
observed thrombocytosis was thought to be associated with compensatory thrombopoietin production. However, 
thrombopoietin assay would have provided inferences.                                                                                                                                
Increased levels of Epo were observed in all the CD4+ groups. High levels of anaemia in increased Epo levels 
observed was probably due to either Epo hyposensitivity or Epo resistance. Increased levels of TNF-α of mixed 
frequencies across the CD4+ cell groups were observed. Minimal increases in IL-6 were also observed. It was 
thought that increases in the levels of the two cytokines were inadequate to effectively inhibit Epo synthesis. The 
observed increases in CRP in all the CD4+ cell groups were thought to be due to active inflammation associated 
with HIV infection or due to chronic infection. Establishment: of gender – based reference ranges for WBC values 
and of African - based reference values for Epo, TNF-α, IL-6 and CRP parameters was recommended. Levels of 
rouleaux formation and targeting of erythrocytes together with CD4+ cell counts as markers of HIV/AIDS disease 
severity was recommended. Further studies on the observed changes over longer study periods was recommended. 
Clinical trial-based studies on the effect of Epo hyposensitivity on use of recombinant human erythropoietin in 
managing anaemia in HIV were recommended. Monitoring the observed changes in haematological parameters, the 
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proinflammatory proteins and Epo in ARV –treated and ARV-naïve HIV patients separately was recommended 
7. Study Limitations   
The recruitment of study respondents was not randomized and this may have reduced the strength of making 
population inferences of the studied characteristics. The details of antiretroviral therapy regimens and therapies for 
HIV- coinfections were not put into account in this research work. The reagents employed for Epo, TNF and IL-6 
assays were recommended for research use only. Limited work has been done in Sub-Saharan Africa on Epo, TNF-
α, IL-6 and CRP parameters and this hindered inter-laboratory comparison of the results obtained. 
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